As you know, the debate on how to get ready the world for another pandemic isn’t ending soon. After more than a year governments accepted the Pandemic Agreement of the World Health Organization; negotiations on its crucial feature are underway: how will countries share data on pathogens and share the profit derived from medical research within the developing countries? NGOs are nowadays putting more pressure on developed countries, stating that they aren’t negotiating enough within the Pandemic Agreement on global health inequity for NGOs that are busy with medical assistance and humanitarian response. The present negotiations may impact if the community that you live in will get vaccines, treatments, diagnoses, and other health devices during the new pandemic at this time.
Why NGOs Are Raising Concerns
A group of 15 civil society organizations, including Oxfam and Medicus Mundi, has asked a UN human rights expert to examine what they describe as delays and obstacles in the ongoing negotiations.
Their concern focuses largely on the Pathogen Access and Benefit-Sharing (PABS) system.
The basic idea is that countries should be able to share pathogen samples and genetic information during health emergencies, while also ensuring that countries contributing those resources can benefit from the vaccines, treatments, and diagnostics developed from them.
For NGOs, this is not simply a technical discussion.
It is about fairness in global healthcare.
What Is the Pandemic Agreement Trying to Solve?
And the calls were stronger, of course, for an international framework with a better plan. The WHO is currently negotiating the terms of a new pandemic agreement aimed at bolstering global efforts on preventing, preparing for, and responding to future outbreaks. But the specifics of this deal still have to be figured out—and negotiating them has proved challenging.
One of the central conflicts is how to incentivize research without ensuring sharing-based incentives for countries with samples of pathogens and data to receive an adequate cut in returns.
In the COVID-19 era, vast inequalities in access to diagnostics, therapies, and vaccines became apparent even as global pharmaceutical research progressed with relative speed. Many of the low-income nations lacked the purchasing power and the market power to access the basics of medical intervention in the crisis.
This experience
Why Pathogen Sharing Matters
When a new infectious disease appears, scientists need information quickly.
Samples, genetic sequences, and other pathogen-related data can help researchers understand how a disease is spreading and develop vaccines, treatments, and diagnostic tools.
But the countries where these pathogens are identified or collected may not always have equal access to the products that result from that research.
This creates a difficult imbalance.
A country may contribute valuable biological information while pharmaceutical companies and wealthier countries have greater access to the resulting products.
NGOs argue that future global health systems should avoid repeating this pattern.
The Lessons From COVID-19
The COVID-19 pandemic remains one of the strongest examples of why this debate matters.
The development of vaccines happened at unprecedented speed, but access was uneven. For many developing countries, obtaining sufficient vaccines and treatments took much longer.
Civil society organizations argue that global health preparedness should therefore focus not only on developing medical products quickly but also on making sure those products are available and affordable across regions.
For NGOs working in health and development, this is particularly important because they often work with communities that are already vulnerable to weak healthcare systems and limited resources.
The Debate Over Pharmaceutical Companies
One of the most complicated parts of the negotiations involves the role of pharmaceutical companies.
Some NGOs are calling for stronger requirements that could allow manufacturers in developing countries to produce medicines or vaccines through licensing arrangements.
However, some wealthy countries have raised concerns that mandatory requirements could discourage investment and pharmaceutical research.
This creates a difficult policy challenge.
Governments want to encourage innovation and research, but civil society groups argue that innovation should also lead to fair access.
Finding a workable middle ground is one of the biggest challenges facing the negotiations.
Why This Matters to NGOs
At first glance, international pandemic negotiations may seem far removed from everyday NGO work.
But the outcome could have a significant impact on organizations working in healthcare, humanitarian response, community development, and public health.
NGOs are often among the organizations supporting communities during health emergencies. They may help with disease prevention, health education, vaccination awareness, healthcare access, emergency response, and public health communication.
If future pandemic systems are more equitable and better coordinated, NGOs could have stronger tools and partnerships for responding to health emergencies.
Global Health Needs More Than Technology
One of the biggest lessons from the pandemic is that developing a vaccine is only part of the solution.
People also need healthcare systems capable of delivering it.
They need accurate information, trained health workers, reliable supply chains, and affordable access to medicines and diagnostics.
This is why NGOs continue to emphasize that global pandemic preparedness must consider the realities faced by communities on the ground.
A medical breakthrough has limited value if the people who need it cannot access it.
Developing Countries Want a Fairer System
The debate also highlights concerns from countries that have historically had less influence over global pharmaceutical production.
Many developing countries provide biological samples and information that can contribute to scientific research, but they may not have the manufacturing capacity or purchasing power needed to access the final products quickly.
A stronger benefit-sharing system could help address this imbalance.
For NGOs, this is closely connected to the broader idea of global health equity—ensuring that a person’s location or a country’s income does not determine whether they receive life-saving medical support during a health emergency.
The Negotiations Could Shape Future Pandemic Response
The current negotiations are expected to continue as countries work toward resolving disagreements surrounding the pathogen access and benefit-sharing system.
The process has already taken longer than many hoped.
For civil society organizations, the delay is concerning because another pandemic could emerge before countries have fully established the systems they are negotiating today.
The longer the process takes, the longer the world remains without a fully operational framework for this particular area of pandemic cooperation.
What NGOs Can Learn From the Debate
For NGOs, the discussion highlights the importance of staying engaged with global health policy.
Organizations do not need to participate directly in international negotiations to contribute.
They can follow policy developments, communicate community needs, participate in civil society networks, and share evidence from their work.
Local NGOs, in particular, can provide valuable perspectives on whether global health policies actually work for communities.
Their experience can help policymakers understand the difference between a policy that looks effective on paper and one that works in real-world conditions.
A Bigger Conversation About Global Health Equity
The dispute surrounding the Pandemic Agreement reflects a much larger issue.
The world has enormous scientific and medical capabilities, but access to those capabilities remains unequal.
The next generation of global health agreements will need to address both sides of the problem: how to encourage innovation and how to make sure innovation benefits everyone.
That will require governments, pharmaceutical companies, international organizations, researchers, and civil society groups to work together.
NGOs have an important role in that conversation because they bring the perspective of communities that are often most affected when global health systems fail.
Why This Matters Before the Next Pandemic
A future worldwide health crisis might present itself in a manner dissimilar to that of COVID-19.
Its transmission could be more rapid, it might impact varied demographic groups, or it could necessitate entirely distinct pharmaceutical treatments and immunizations.
The disparity in accessibility, which was starkly evident throughout the COVID-19 pandemic, is something that should not recur.
The ongoing discussions offer a chance to establish more robust frameworks prior to the onset of another catastrophe.
This entails reaching a consensus on the methods for exchanging data and biological substances, the processes for allocating advantages, and the ways in which nations possessing fewer means can obtain crucial medical supplies.
Delaying the resolution of these matters until the subsequent pandemic arises could prove substantially more expensive.
Final Thoughts
The heated negotiation of the WHO Pandemic Agreement clearly reflects the reality that preparedness against the future pandemic requires more than new vaccines and emergency protocols. It also requires issues like trust, equity, access, and cooperation between nations. For NGOs, one big question stemming from the worries raised in the statement was about the right for developing nations to enjoy equitable opportunities in accessing or benefiting from the goods developed from the knowledge, samples, and data shared by them for global health studies.
With NGOs directly speaking for vulnerable populations, this translates to a stronger global health system that ought not just be able to innovate medical breakthroughs but be able to enable these breakthroughs to benefit those who need them.
While future global health preparedness shall be measured not just by how soon a vaccine or cure is achieved globally but also by how widely and equitably it is achieved worldwide, which justifies the voice of NGOs and civil society groups in this global health discussion.
.
